SOCS proteins in macrophage polarization and function

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Wilson, Heather M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Inflammation; M1; M2; Macrophage; Suppressor of cytokine signaling proteins

Indexed keywords

EID: 84905656745     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00357     Document Type: Note

References (50)

1. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 11:723-37. doi: 10.1038/nri3073
2. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol (2000) 164:6166-73. doi:10.4049/jimmunol.164.12.6166
3. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest (2012) 122:787-95. doi:10.1172/JCI59643
4. Whyte CS, Bishop ET, Rückerl D, Gaspar-Pereira S, Barker RN, Allen JE, et al. Suppressor of cytokine signaling (SOCS)1 is a key determinant of differential macrophage activation and function. J Leukoc Biol (2011) 90:845-54. doi:10.1189/jlb.1110644
5. Liu Y, Stewart KN, Bishop ET, Marek CM, Kluth DC, Rees AJ, et al. Unique expression of suppressor of cytokine signaling 3 is essential for classical macrophage activation in rodents in vitro and in vivo. J Immunol (2008) 180:6270-8. doi:10.4049/jimmunol.180.9.6270
6. Arnold CE, Whyte CS, Gordon P, Barker RN, Rees AJ, Wilson HM. A critical role for suppressor of cytokine signalling 3 in promoting M1 macrophage activation and function in vitro and in vivo. Immunology (2014) 141:96-110. doi:10.1111/imm.12173
7. Qin H, Holdbrooks AT, Liu Y, Reynolds SL, Yanagisawa LL, Benveniste EN. SOCS3 deficiency promotes M1 macrophage polarization and inflammation. J Immunol (2012) 189:3439-48. doi:10.4049/jimmunol.1201168
8. Strebovsky J, Walker P, Dalpke AH. Suppressor of cytokine signaling proteins as regulators of innate immune signaling. Front Biosci (2012) 17:1627-39.
9. Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signaling, and immune regulation. Nat Rev Immunol (2007) 7:454-65. doi:10.1038/nri2093
10. Madonna S, Scarponi C, De Pità O, Albanesi C. Suppressor of cytokine signaling 1 inhibits IFN-gamma inflammatory signaling in human keratinocytes by sustaining ERK1/2 activation. FASEB J (2008) 22:3287-97. doi:10.1096/fj.08-106831
11. Lu Y, Fukuyama S, Yoshida R, Kobayashi T, Saeki K, Shiraishi H, et al. Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic. J Biol Chem (2006) 281:36683-90. doi:10.1074/jbc.M607374200
12. Wang YC, He F, Feng F, Liu XW, Dong GY, Qin HY. Notch signaling determines the M1 versus M2 polarization of macrophages in antitumor immune responses. Cancer Res (2010) 70:4840-9. doi:10.1158/0008-5472.CAN-10-0269
13. Puhr M, Santer FR, Neuwirt H, Marcias G, Hobisch A, Culig Z. SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signalling. Endocr Relat Cancer (2010) 17:525-38. doi:10.1677/ERC-10-0007
14. Nakagawa R, Naka T, Tsutsui H, Fujimoto M, Kimura A, Abe T, et al. SOCS-1 participates in negative regulation of LPS responses. Immunity (2002) 17:677-87. doi:10.1016/S1074-7613(02)00449-1
15. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou YC, Wulf G, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell (2003) 12:1413-26. doi:10.1016/S1097-2765(03)00490-8
16. Kinjyo I, Hanada T, Inagaki-Ohara K, Mori H, Aki D, Ohishi M, et al. SOCS1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity (2002) 17:583-91. doi:10.1016/S1074-7613(02)00446-6
17. Sachithanandan N, Graham KL, Galic S, Honeyman JE, Fynch SL, Hewitt KA, et al. Macrophage deletion of SOCS1 increases sensitivity to LPS and palmitic acid and results in systemic inflammation and hepatic insulin resistance. Diabetes (2011) 60:2023-31. doi:10.2337/db11-0259
18. Baetz A, Frey M, Heeg K, Dalpke AH. Suppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem (2004) 279:54708-15. doi:10.1074/jbc.M410992200
19. Gingras S, Parganas E, de Pauw A, Ihle JN, Murray PJ. Re-examination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of toll-like receptor signaling. J Biol Chem (2004) 279:54702-7. doi:10.1074/jbc.M411043200
20. Cheng C, Huang C, Ma TT, Bian EB, He Y, Zhang L, et al. SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages. Toxicol Lett (2014) 225:488-97. doi:10.1016/j.toxlet.2013.12.023
21. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 104:1604-9. doi:10.1073/pnas.0610731104
22. Ruggiero T, Trabucchi M, De Santa F, Zupo S, Harfe BD, McManus MT, et al. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J (2009) 23:2898-908. doi:10.1096/fj.09-131342
23. Androulidaki A, Iliopoulos D, Arranz A, Doxaki C, Schworer S, Zacharioudaki V. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity (2009) 31:220-31. doi:10.1016/j.immuni.2009.06.024
24. Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ. Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol (2004) 172:7565-73. doi:10.4049/jimmunol.172.12.7565
25. Sly LM, Rauh MJ, Kalesnikoff J, Song CH, Krystal G. LPS-induced upregulation of SHIP is essential for endotoxin tolerance. Immunity (2004) 21:227-39. doi:10.1016/j.immuni.2004.07.010
26. Dickensheets HN, Vazquez N, Sheikh F, Gingras S, Murray PJ, Ryan JJ, et al. Suppressor of cytokine signaling-1 is an IL-4-inducible gene in macrophages and feedback inhibits IL-4 signaling. Genes Immun (2007) 8:21-7. doi:10.1038/sj.gene.6364352
27. O'Connor JC, Sherry CL, Guest CB, Freund GG. Type 2 diabetes impairs insulin receptor substrate-2-mediated phosphatidylinositol 3-kinase activity in primary macrophages to induce a state of cytokine resistance to IL-4 in association with overexpression of suppressor of cytokine signaling-3. J Immunol (2007) 178:6886-93. doi:10.4049/jimmunol.178.11.6886
28. Pesce JT, Ramalingam TR, Mentink-Kane MM, Wilson MS, El Kasmi KC, Smith AM, et al. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog (2009) 5:e1000371. doi:10.1371/journal.ppat.1000371
29. Esper L, Roman-Campos D, Lara A, Brant F, Castro LL, Barroso A, et al. Role of SOCS2 in modulating heart damage and function in a murine model of acute Chagas disease. Am J Pathol (2012) 181:130-40. doi:10.1016/j.ajpath.2012.03.042
30. Zadjali F, Santana-Farre R, Vesterlund M, Carow B, Mirecki-Garrido M, Hernandez-Hernandez I, et al. In SOCS2 KO mice, there was a reduction in both parasitemia and the expression of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), IL-6, IL-10, SOCS1, and SOCS3 in the spleen. FASEB J (2012) 26:3282-91. doi:10.1096/fj.12-205583
31. Posselt G, Schwarz H, Duschl A, Horejs-Hoeck J. Suppressor of cytokine signaling 2 is a feedback inhibitor of TLR-induced activation in human monocyte-derived dendritic cells. J Immunol (2011) 187:2875-84. doi:10.4049/jimmunol.1003348
32. Whitmarsh RJ, Gray CM, Gregg B, Christian DA, May MJ, Murray PJ, et al. A critical role for SOCS3 in innate resistance to Toxoplasma gondii. Cell Host Microbe (2011) 10:224-36. doi:10.1016/j.chom.2011.07.009
33. Lang R, Pauleau AL, Parganas E, Takahashi Y, Mages J, Ihle JN. SOCS3 regulates the plasticity of gp130 signaling. Nat Immunol (2003) 4:546-50. doi:10.1038/ni932
34. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, et al. Negatively regulates IL-6 signaling in vivo. Nat Immunol (2003) 4:540-5. doi:10.1038/ni931
35. Yasukawa H, Ohishi M, Mori H, Murakami M, Chinen T, Aki D. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat Immunol (2003) 4:551-6. doi:10.1038/ni938
36. Liu X, Zhang Y, Yu Y, Yang X, Cao X. SOCS3 promotes TLR4 response in macrophages by feedback inhibiting TGF-beta1/Smad3 signaling. Mol Immunol (2008) 45:1405-13. doi:10.1016/j.molimm.2007.08.018
37. Hiwatashi K, Tamiya T, Hasegawa E, Fukaya T, Hashimoto M, Kakoi K, et al. Suppression of SOCS3 in macrophages prevents cancer metastasis by modifying macrophage phase and MCP2/CCL8 induction. Cancer Lett (2011) 308:172-80. doi:10.1016/j.canlet.2011.04.024
38. Matsumura Y, Kobayashi T, Ichiyama K, Yoshida R, Hashimoto M, Takimoto T, et al. Selective expansion of foxp3-positive regulatory T cells and immunosuppression by suppressors of cytokine signaling 3-deficient dendritic cells. J Immunol (2007) 179:2170-9. doi:10.4049/jimmunol.179.4.2170
39. Qin H, Yeh WI, De Sarno P, Holdbrooks AT, Liu Y, Muldowney MT, et al. Signal transducer and activator of transcription-3/suppressor of cytokine signaling-3 (STAT3/SOCS3) axis in myeloid cells regulates neuroinflammation. Proc Natl Acad Sci U S A (2012) 109:5004-9. doi:10.1073/pnas.1117218109
40. Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, Drake S, et al. SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest (2006) 116:1571-81. doi:10.1172/JCI25660
41. Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopes-Franco O, et al. Suppressors of cytokine signalling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 29:525-31. doi:10.1161/ATVBAHA.108.173781
42. Tang J, Kozaki K, Farr AG, Martin PJ, Lindahl P, Betsholtz C, et al. The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice. Am J Pathol (2005) 167:901-12. doi:10.1016/S0002-9440(10)62061-5
43. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. Eur J Vasc Endovasc Surg (2012) 44:491-7. doi:10.1016/j.ejvs.2012.08.005
44. Grothusen C, Schuett H, Hillmer A, Lumpe S, Grote K, Ballmaier M. Role of suppressor of cytokine signaling-1 in murine atherosclerosis. PLoS One (2012) 7:e51608. doi:10.1371/journal.pone.0051608
45. Yamamoto TYH, Koga M. Lacking the SOCS3 Gene in macrophages prevents the development of atherosclerosis in ApoE deficient mice. Circ J (2007) 71:170.
46. Li Y, de Haar C, Peppelenbosch MP, van der Woude CJ. SOCS3 in immune regulation of inflammatory bowel disease and inflammatory bowel disease-related cancer. Cytokine Growth Factor Rev (2012) 23:127-38. doi:10.1016/j.cytogfr.2012.04.005
47. Hontecillas R, Horne WT, Climent M, Guri AJ, Evans C, Zhang Y. Immunoregulatory mechanisms of macrophage PPAR-γ in mice with experimental inflammatory bowel disease. Mucosal Immunol (2011) 4:304-13. doi:10.1038/mi.2010.75
48. Heys SD, Stewart KN, McKenzie EJ, Miller ID, Wong SY, Sellar G, et al. Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat (2009) 135:539-48. doi:10.1007/s10549-012-2190-6
49. Hashimoto M, Ayada T, Kinjyo I, Hiwatashi K, Yoshida H, Okada Y, et al. Silencing of SOCS1 in macrophages suppresses tumor development by enhancing antitumor inflammation. Cancer Sci (2009) 100:730-6. doi:10.1111/j.1349-7006.2009.01098.x
50. Scheller EL, Hankenson KD, Reuben JS, Krebsbach PH. Zoledronic acid inhibits macrophage SOCS3 expression and enhances cytokine production. J Cell Biochem (2011) 112:3364-72. doi:10.1002/jcb.23267